Nikaia Pharmaceuticals
- Biotech or pharma, therapeutic R&D
At Nikaia Pharmaceuticals, we are pioneering a groundbreaking approach to treating cancer and autoimmune diseases by selectively blocking NIK (NF-κB-inducing kinase). We are advancing two parallel programs: in oncology, we are optimizing our lead compounds and are confident in identifying our candidate by the end of 2025. For the autoimmune program, we are focused on achieving in vivo proof of concept.
Address
NiceFrance
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}